People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Axonis Therapeutics, Inc. | — | Biotechnology | Series C | $46.0M | $366.2M | 2024 |
Shane . Hegarty at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Shane . Hegarty on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Corey Goodman | 1 | 13 |
| Brock Reeve | 1 | 2 |
| Donald J. Manning, M.D., Ph.D | 1 | 1 |
| Jeffrey Imbaro | 1 | 1 |
| Joanna Stanicka | 1 | 1 |
| Jonathan J. Leff | 1 | 1 |
| Raymond J. Kelleher | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.